Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium
Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))))), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent will be presented as a poster at the 2024 AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), to be held in Barcelona, Spain (October 23-25, 2024). The patients were enrolled in the biomarker-enriched, Cohort 8 of the proof of concept study and were preselected for CDKN2A and/or CDKN2B abnormalities.
Cyclacel Pharmaceuticals, Inc. (纳斯达克:CYCC, 纳斯达克:CYCCP, Cyclacel, 或公司), 一家开发创新癌症药物的生物制药公司, 今天宣布, 来自参加fadraciclib单药物作为单药物进行的第2阶段065-101临床研究中12名患有晚期固体瘤的病人的初步安全性和有效性数据将被作为海报展示在2024年AACR-新华保险-EORTC第36届分子靶点和癌症治疗研讨会(“三重会议”)上，该会议将于2024年10月23日至25日在西班牙巴塞罗那举行。这些患者是超过概念研究中生物标志富集的第8队列中的受试者, 并且已经预先选择了CDKN2A和/或CDKN20亿异常。
Details of the presentation are listed below:
以下是演讲的详细内容:
| Title: | Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations |
| Abstract Number: | 59 |
| Session: | Molecular Targeted Agents |
| Date/Time: | 12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23, 2024 |
| 标题： | Fadraciclib是一种口服CDK2/9抑制剂，在患有CDKN2A和/或CDKN20亿基因改变的患者中，该患者患有晚期实体瘤和淋巴瘤 |
| 摘要编号： | 59 |
| 会议主题： | 分子靶向药物 |
| 日期/时间: | 2024年10月23日（星期三）下午12:00至下午7:00中欧夏令时间 |
